Tina Costacou1, Trevor J Orchard2. 1. Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, 15213, USA. Electronic address: CostacouT@edc.pitt.edu. 2. Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, 15213, USA.
Abstract
AIMS: The Haptoglobin (HP) 2-2 genotype increases cardiovascular diabetes complication incidence. In type 1 diabetes, HP 2-2 also predicts declining kidney function and end-stage renal disease. We investigated whether HP 2-2 predisposes to cardio-renal mortality, while considering other causes of death as competing risks. METHODS: Individuals with type 1 diabetes and HP data available (n=486; mean baseline age, 27 and duration, 19 years) were selected for study. Vital status was assessed as of 8/31/2014. The underlying cause of death was determined and classified based on standardized procedures. RESULTS: During 25 years of follow-up, 79 (16.3%) cardio-renal deaths and 43 (8.8%) deaths related to other causes occurred. Although total mortality did not differ by HP (25.4% with HP 1 versus 24.6% with HP 2-2, p=0.84), a greater proportion of HP 2-2 carriers exhibited a cardio-renal death (19.0 versus 14.2, p=0.05). In time-to-event analyses, HP 2-2 was associated with a statistically significant increase of the sub-distribution hazard ratio for cardio-renal mortality (HR=1.64, p=0.03), although this effect was somewhat attenuated after multivariable adjustment (HR=1.58, p=0.05). CONCLUSIONS: Our results suggest that in addition to predicting the incidence of cardio-renal complications, HP 2-2 also increases susceptibility for cardio-renal mortality in type 1 diabetes. These findings require validation in other cohorts.
AIMS: The Haptoglobin (HP) 2-2 genotype increases cardiovascular diabetes complication incidence. In type 1 diabetes, HP 2-2 also predicts declining kidney function and end-stage renal disease. We investigated whether HP 2-2 predisposes to cardio-renal mortality, while considering other causes of death as competing risks. METHODS: Individuals with type 1 diabetes and HP data available (n=486; mean baseline age, 27 and duration, 19 years) were selected for study. Vital status was assessed as of 8/31/2014. The underlying cause of death was determined and classified based on standardized procedures. RESULTS: During 25 years of follow-up, 79 (16.3%) cardio-renal deaths and 43 (8.8%) deaths related to other causes occurred. Although total mortality did not differ by HP (25.4% with HP 1 versus 24.6% with HP 2-2, p=0.84), a greater proportion of HP 2-2 carriers exhibited a cardio-renal death (19.0 versus 14.2, p=0.05). In time-to-event analyses, HP 2-2 was associated with a statistically significant increase of the sub-distribution hazard ratio for cardio-renal mortality (HR=1.64, p=0.03), although this effect was somewhat attenuated after multivariable adjustment (HR=1.58, p=0.05). CONCLUSIONS: Our results suggest that in addition to predicting the incidence of cardio-renal complications, HP 2-2 also increases susceptibility for cardio-renal mortality in type 1 diabetes. These findings require validation in other cohorts.
Authors: T J Orchard; J S Dorman; R E Maser; D J Becker; A L Drash; D Ellis; R E LaPorte; L H Kuller Journal: Diabetes Date: 1990-09 Impact factor: 9.461
Authors: Mahmoud Suleiman; Doron Aronson; Rabea Asleh; Michael R Kapeliovich; Ariel Roguin; Simcha R Meisel; Michael Shochat; Abeer Sulieman; Shimon A Reisner; Walter Markiewicz; Haim Hammerman; Rachel Lotan; Nina S Levy; Andrew P Levy Journal: Diabetes Date: 2005-09 Impact factor: 9.461
Authors: Rabea Asleh; Rachael Miller-Lotan; Michael Aviram; Tony Hayek; Michael Yulish; Joanne E Levy; Benjamin Miller; Shany Blum; Uzi Milman; Chen Shapira; Andrew P Levy Journal: Circ Res Date: 2006-11-02 Impact factor: 17.367
Authors: Trevor J Orchard; Jye-Yu C Backlund; Tina Costacou; Patricia Cleary; Maria Lopes-Virella; Andrew P Levy; John M Lachin Journal: J Diabetes Complications Date: 2016-07-25 Impact factor: 2.852